z-logo
open-access-imgOpen Access
p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
Author(s) -
Liang Zhu,
Ed Harlow,
Brian David Dynlacht
Publication year - 1995
Publication title -
genes and development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.136
H-Index - 438
eISSN - 1549-5477
pISSN - 0890-9369
DOI - 10.1101/gad.9.14.1740
Subject(s) - cyclin dependent kinase , cyclin a , cyclin dependent kinase complex , cyclin a2 , cyclin e , cyclin d , cyclin dependent kinase 2 , biology , microbiology and biotechnology , cyclin , cyclin b , cancer research , biochemistry , kinase , cell cycle , protein kinase a , cell
The kinase activities of the cyclin/cdk complexes can be regulated in a number of ways. The most recently discovered mechanism of regulation is the association of cdk inhibitors (CKIs), such as p21, p27, and p57, with these complexes. In this report we demonstrate that the pRB-related protein p107, like the p21 family of cdk inhibitors, can inhibit the phosphorylation of target substrates by cyclin A/cdk2 and cyclin E/cdk2 complexes, and the associations of p107 and p21 with cyclin/cdk2 rely on a structurally and functionally related interaction domain. Furthermore, interactions between p107 or p21 with cyclin/cdk2 complexes are mutually exclusive. In cells treated with DNA-damaging agents elevated levels of p21 cause a dissociation of p107/cyclin/cdk2 complexes to yield p21/cyclin/cdk2 complexes. Finally, the consequences of cyclin/cdk2 interactions with p107 have been examined. The activation of the p107-bound cyclin/cdk kinases leads to dissociation of p107 from the transcription factor E2F. Together, these results suggest that cyclin/cdk complexes can be regulated by protein molecules from different families in a mutually exclusive manner in response to certain signals and that these inhibitory proteins may have a potential role in regulating macromolecular assembly.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here